Sinusoidal Obstruction Syndrome (SOS)
Also known as: Sinusoidal Obstruction Syndrome / Hepatic sinusoidal obstruction syndrome / Hepatic veno-occlusive disease / Veno-occlusive disease of the liver (disorder) / Venoocclusive syndrome of the liver / Venoocclusive liver disease
Drug | Drug Name | Drug Description |
---|---|---|
DB04932 | Defibrotide | A mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB04932 | Defibrotide | Adenosine receptor A1 | target |
DB04932 | Defibrotide | Adenosine receptor A2a | target |
DB04932 | Defibrotide | Adenosine receptor A2b | target |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB06151 | Acetylcysteine | 2 | Not Yet Recruiting | 1 |
DB04932 | Defibrotide | 2 | Not Yet Recruiting | 1 |
DB04932 | Defibrotide | 2 | Recruiting | 1 |
DB14099 | 1,2-Distearoyllecithin | 4 | Withdrawn | 1 |
DB14105 | Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) | 4 | Withdrawn | 1 |
DB11104 | Sulfur hexafluoride | 4 | Withdrawn | 1 |